Iadademstat with hypomethylating agent for MDS
Part of Blood & lymphatic clinical trials.
This trial tests a new oral medication (iadademstat) combined with a standard therapy called a hypomethylating agent for people with higher-risk myelodysplastic syndromes (MDS) or related blood cancers. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of MDS, MDS/MPN, or CMML that is intermediate, high, or very high risk.
- You have not had prior treatment with a hypomethylating agent (like azacitidine or decitabine) or an LSD1 inhibitor.
- You are able to swallow pills, and your weight is at least 50 kg (110 lbs).
- Your kidney and liver function are within certain limits, and your white blood cell count is below a certain level.
- You are not pregnant or breastfeeding, and you agree to use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This early-phase study tests whether combining two “epigenetic” medicines—azacitidine and decitabine—can improve outcomes for certain bone marrow cancers. It may help if you have a type of myelodysplastic syndrome (MDS) or MDS/MPN overlap that is expected to be sensitive to these medicines.
This trial tests a pill called chidamide for people with a bone marrow condition called myelodysplastic syndromes (MDS). It may help improve blood counts and reduce the need for transfusions.
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
This trial tests a new drug combination (iadademstat plus azacitidine and venetoclax) for people with newly diagnosed AML who cannot have or do not want standard intensive chemotherapy. The goal is to see if adding iadademstat makes the treatment work better.
This trial tests whether adding bexmarilimab to standard azacitidine treatment helps people with higher-risk myelodysplastic syndromes (MDS), a type of blood cancer. It compares this combination to azacitidine plus a placebo to see which is more effective.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.